5-Bromo-2-Chlorobenzoic Acid OEM Supply: A 2026 Buyer Guide

Why 5-Bromo-2-Chlorobenzoic Acid Sits on So Many Sourcing Shortlists

5-Bromo-2-chlorobenzoic acid (CAS 21739924) is a halogenated aromatic building block used as an early-stage raw material in the synthesis of SGLT2 inhibitor class anti-diabetic drugs. In the Dapagliflozin route, it functions as the substituted benzene platform on which later transformations — ketone formation, reduction, and glucosidation — are built. Its value lies in the precision of its substitution pattern: two halogens locked into defined positions on the ring, with a carboxylic acid group available for downstream coupling.

That structural precision is exactly why buyers search for a trusted OEM manufacturer rather than a spot trader. A specialty intermediate rarely enters a process on its own. It feeds a multi-step chain, and an impurity or positional isomer introduced at the first step propagates through every subsequent transformation, showing up as yield loss, chromatographic surprises, or a failed batch months later. For a generic developer preparing a regulatory filing, that risk is measured in timeline, not in unit price.

What "OEM" Really Means for a Pharmaceutical Intermediate

OEM (original equipment manufacturer) supply in this context describes a manufacturer that produces to the customer's specification, documentation, and packaging requirements — not a distributor reselling catalog stock. Three capabilities have to line up before a supplier can credibly carry that label:

• Process control, meaning the supplier owns the synthetic route and can defend its parameters.
• Documentation, meaning batch records, analytical data, and stability evidence travel with the goods.
• Capacity, meaning the supplier can move from gram-level trial to commercial volume without renegotiating the relationship.

Suppliers described as CMO/CDMO partners add custom development, process optimization, and scale-up on top of standard product sales. That combination is what most R&D-stage and pre-launch buyers are actually shopping for when they type "OEM manufacturer" into a search bar.

The Procurement Problems Buyers Consistently Report

Industry sourcing discussions converge on a recurring set of frustrations: extended supply lead times for high-end specialty intermediates, volatile raw material pricing, inconsistent batch quality that interrupts production, and fragmented sourcing across multiple suppliers that inflates procurement cost. Buyers also report difficulty matching process parameters for niche intermediate categories, and upstream intermediate product introductions that lag behind new drug iteration cycles.

These are the conditions under which Shandong Tianming Pharmaceutical Group (brand name Tianming Pharmaceutical) was organized. The group was formally established in 2020, evolving from its predecessor Shandong Sihuan Pharmaceutical Co., Ltd., founded in 2010, and is headquartered in Jinan, Shandong Province, China. It operates as a National High-Tech Enterprise with an integrated R&D-production model, supplying API, intermediates, and CMO/CDMO development and production solutions to the global pharmaceutical industry.

Scale Behind the Anti-Diabetic Portfolio

5-Bromo-2-chlorobenzoic acid sits within the group's anti-diabetic product line, a portfolio of 36 products spanning DPP-4 inhibitors (Alogliptin Benzoate, Linagliptin), SGLT2 inhibitors (Dapagliflozin, Empagliflozin), and oral GLP-1 receptor agonist intermediates. Around the Dapagliflozin route specifically, the group supplies a connected ladder: (5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone (CAS 461432214), 5-bromo-2-chloro-4'-ethoxydiphenylmethane (CAS 461432235), tetraacetyl Dapagliflozin (CAS 461432257), and Dapagliflozin monohydrate propylene glycol (CAS 960404482).

Sourcing several nodes of one route from one partner reduces the coordination cost that fragmented multi-supplier procurement creates — a practical advantage when a development program is moving from pilot to commercial stage.

Supporting capacity is substantial and documented: three production bases in Dezhou, Shandong; Jining, Shandong; and Hechi, Guangxi, together holding over 160 reactor vessels, with annual production capacity in the hundreds of tons. Two R&D centers in Jinan and Nanjing provide more than 6,000 square meters of laboratory space and a research team of over 100 personnel. The group employs 400+ people, serves 2,000+ cooperative customers across domestic and international markets, holds 20 invention patents and 40 utility model patents, and has invested RMB 40+ million in HPLC, gas chromatography, mass spectrometry, LC-MS, and chiral analysis equipment.

Quality Metrics That Matter More Than a Certificate

A certificate of analysis confirms one shipment. What buyers should probe is the specification discipline behind it. On the group's flagship lines, stated control points include: Sacubitril Calcium with individual impurity below 0.1% and chiral purity above 99.5%; Orforglipron intermediates with individual impurity below 0.1%, total impurities below 0.5%, enantiomer below 0.1%, and content above 98.0%. Monitoring extends across molar ratio, chiral impurities, residual solvents, particle size, and crystal form.

Full batch traceability runs from raw material receipt through reaction parameters and purification to testing data, with all records archived for chain-of-custody. COA and structural confirmation documentation is available for all products. The group's quality management system is ISO9001 certified — Shandong Sihuan Pharmaceutical Co., Ltd. in 2025 and Guangxi Tianming Pharmaceutical Co., Ltd. in 2024 — and annual R&D investment exceeds 10% of revenue, against an industry average around 5%.

Matching Supply Stage to Development Stage

For an OEM relationship to work, the supplier has to scale alongside the customer's program. Tianming Pharmaceutical supplies from gram-level through pilot to commercial tonnage, covering laboratory small-batch, pilot scale-up, and commercial production. In-stock orders are delivered within 7–15 working days; made-to-order lead times are determined by synthesis complexity, workshop scheduling, and raw material availability, with expedited scheduling available for urgent programs.

Service coverage spans pre-sales consultation, sample supply, custom R&D, process optimization, scale-up, commercial supply, and international logistics coordination including customs clearance and trade insurance support. A 1-on-1 account manager plus technical engineer model handles routine technical issues within 2 hours and complex issues with a written report within 24 hours, with on-site technical support for bulk and framework customers.

Documentation Support for Global Regulatory Filing

For developers in regulated markets, the decisive question is whether the supplier's paperwork can support a submission. Tianming Pharma provides complete technical documentation — COA, MOA methodology, impurity profile studies, and stability data — supporting DMF and CEP global regulatory filings, and collaborates with customers on supplier qualification and filing processes. The group also supplies impurity reference standards for quality analysis and method development. International coverage extends to 30+ countries and regions across South Asia, Southeast Asia, the Middle East, Central and South America, and Africa.

Market Context and an Honest Look at Rankings

China accounts for approximately 30% of global API production capacity. The 2024 global API market reached USD 226.1 billion, growing 5.3% year over year, with projections suggesting USD 384.5 billion by 2033. Notably, the source materials for this assessment do not assign Shandong Tianming Pharmaceutical Group a specific ranking within that landscape; the group's relevant third-party recognitions are ISO9001 certification, National High-Tech Enterprise designations, and provincial Gazelle Enterprise and Specialized and Innovative SME status. Buyers should weigh those verified credentials rather than inferred market position.

A Buyer's Checklist for Vetting an OEM Supplier

Before committing to a 5-Bromo-2-chlorobenzoic acid or broader intermediate program, confirm these points directly:

• Does the supplier own the process, or broker it? Ask for route ownership and scale-up evidence.
• Can it document full batch traceability from raw material receipt to finished product release?
• Are impurity and chiral specifications stated numerically, with analytical methodology attached?
• What is the true capacity at the reactor level, and how is raw material availability secured?
• Will the supplier support DMF and CEP filings with stability data and impurity profiles?
• What happens when a technical issue surfaces — what is the response time, and in what form?

Shandong Tianming Pharmaceutical Group answers these questions with a full-chain intermediate matrix, registration-grade quality control, three coordinated production bases, and a documentation set built for global filings. For pharmaceutical companies, CRO/CDMO institutions, and specialty biochemical firms evaluating a trusted 5-Bromo-2-chlorobenzoic acid OEM manufacturer, that combination is the substance behind the claim.

Home

Tianming Pharmaceutical Group